Cardiff Oncology Files Lawsuit Over Onvansertib Patent Rights
I'm LongbridgeAI, I can summarize articles.Cardiff Oncology, Inc. has filed a lawsuit against Nerviano Medical Sciences S.r.L. in the U.S. District Court, challenging claims of breaching a license agreement for the cancer drug onvansertib. Cardiff seeks to compel Nerviano to fulfill the agreement and asserts it did not breach the contract regarding inventorship claims. The outcome may impact Cardiff's control over key intellectual property. Analysts rate CRDF stock as a Buy with a $10.00 price target, though financial performance remains a concern.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Cardiff Oncology ( (CRDF) ) is now available.
On May 19, 2026, Cardiff Oncology, Inc. filed a lawsuit in the U.S. District Court for the Southern District of California against Nerviano Medical Sciences S.r.L., challenging allegations that it materially breached their license agreement for the cancer drug onvansertib. The company is seeking injunctive relief to compel Nerviano to continue performing under the agreement and a declaratory judgment that Cardiff did not breach the contract, after Nerviano claimed Cardiff failed to list an NMS employee as a joint inventor on two U.S. patents and declined to file a joint continuation application.
Cardiff contends the agreement does not obligate it to name NMS employees on inventions it says were made exclusively by Cardiff, nor to make what it characterizes as false or inaccurate inventorship statements to the U.S. Patent and Trademark Office. The dispute underscores the strategic importance of patent rights and licensing terms around onvansertib, with the outcome likely to affect Cardiff’s control over key intellectual property and the continuity of its development efforts for this oncology asset.
The most recent analyst rating on (CRDF) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cardiff Oncology stock, see the CRDF Stock Forecast page.
Spark’s Take on CRDF Stock
According to Spark, TipRanks’ AI Analyst, CRDF is a Neutral.
The score is primarily weighed down by weak financial performance (minimal revenue, large losses, and persistent cash burn), partially offset by a conservatively levered balance sheet and positive pipeline/leadership corporate updates. Technicals are neutral-to-mixed (short-term stabilization but longer-term downtrend), while valuation remains difficult to support due to negative earnings and no dividend yield data.
To see Spark’s full report on CRDF stock, click here.
More about Cardiff Oncology
Cardiff Oncology, Inc. is a biotechnology company focused on developing cancer therapies, including the investigational drug onvansertib. The company operates in the oncology space, concentrating on targeted treatments that leverage proprietary intellectual property to advance its clinical and commercial prospects in the oncology therapeutics market.
Average Trading Volume: 716,057
Technical Sentiment Signal: Sell
Current Market Cap: $114.2M
See more insights into CRDF stock on TipRanks’ Stock Analysis page.